NSE · BALPHARMA
Bal Pharma Ltd.
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹88 Cr with net profit ₹1 Cr — a 1.31% net margin, versus 2% the period before.
Shareholding
As of 2026-09-30
- Promoter50.86%
- Public48.87%
- FII0.28%
15,241 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 2.08× from low to high.
Risk flags
Derived from disclosed data
- Under exchange surveillance — ESM · ESM 1. Trading may carry price bands, periodic call auction or higher margins.
Peer comparison
Pharmaceuticals - Indian - Bulk Drugs & Formln · ranked #70 of 102 by market cap · medians across 50 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | ₹4,19,404 Cr | 33.19 | 5 | 13.74% | 20.29% |
| Zydus Lifesciences Ltd. | ₹1,12,658 Cr | 23.07 | 4.15 | 18.59% | 16.09% |
| Cipla Ltd. | ₹1,08,093 Cr | 30.2 | 3.14 | 11.27% | 12.06% |
| Laurus Labs Limited | ₹1,06,442 Cr | 97.33 | 20.12 | 16.77% | 15.04% |
| Dr Reddys Laboratories Ltd. | ₹1,02,624 Cr | 31.85 | 2.68 | 7.21% | 8.49% |
| Mankind Pharma Limited | ₹91,390 Cr | 42.84 | 5.62 | 11.74% | 13.86% |
| Aurobindo Pharma Ltd. | ₹90,432 Cr | 23.92 | 2.38 | 9.25% | 10.7% |
| Lupin Limited | ₹88,207 Cr | 14.81 | 3.92 | 23.76% | 18.72% |
| Glenmark Pharmaceuticals Ltd. | ₹61,147 Cr | 19.59 | 5.72 | 28.08% | 10.22% |
| Alkem Laboratories Ltd. | ₹59,149 Cr | 25.96 | 4.26 | 16.66% | 14.31% |
| Bal Pharma Ltd.(this company) | ₹129 Cr | 17.9 | 1.58 | 7.64% | 2.15% |
AI analysis
AI-generated · google/gemini-2.5-flashBal Pharma Ltd., operating in the Pharmaceuticals sector, has a market capitalization of Rs 142 Cr. The company reported an EPS of 3.95 and a Price-to-Earnings ratio of 39.5. Its Return on Equity (ROE) stands at 7.64% and Return on Capital Employed (ROCE) at 9.18%.
Positives
- +Promoter holding of 50.8589% is above 50%, indicating significant insider ownership.
- +The current profit margin is 201.5%, suggesting strong profitability in the latest reporting period.
- +No promoter shares are pledged, as indicated by a promoter pledge of 0%.
Negatives
- −Revenue has decreased by 10.65% over the last year.
- −The debt-to-equity ratio is 1.94, which is relatively high.
- −DII shareholding is 0%, indicating no investment by domestic institutional investors.
Financial Performance
In the financial year ending March 2025, Bal Pharma Ltd. reported revenue of Rs 305.2862 Cr, with a net profit of Rs 7.2153 Cr. Over the last year, revenue has decreased by 10.65%. The company's profit margin for the latest period was 201.5%.
Profitability & Returns
The company's Return on Equity (ROE) is 7.64%, while Return on Capital Employed (ROCE) is 9.18%. The Earnings Per Share (EPS) for the latest available period is 3.95. The profit margin stands at 201.5%.
Balance Sheet
Bal Pharma Ltd. has a debt-to-equity ratio of 1.94, indicating a notable reliance on debt financing. The book value per share is Rs 51.65. No information on substantial asset pledges or other specific balance sheet items is provided in the data.
Ownership & Pledges
There are no shares pledged by the promoters.
Data as of — price: 2026-10-26 · financials: Jun 26 · shareholding: Sep 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.